Guessing
no more

Innovation

We strive to bring the technology we create closer to you. Our discoveries in the areas of genomics and artificial intelligence are unique and contribute to the fast-paced fight against cancer.

How ARETEai platform can change the approach to drug discovery?

ARETEai platform is an important step in finding common ground for different experts working towards a single goal - better outcomes of personalized medicine.

No items found.

Targeting Cancer with Precision AI

Our mission is to provide the right therapy for every cancer patient. This is done with the use of artificial intelligence.

No items found.

We simplify the functioning of genomics pipelines

The roots of MNM go back to the world of science, where sharing knowledge is essential.

No items found.

Introducing Random Similarity Forests

Random Similarity Forest is a machine learning algorithm capable of handling datasets with features of arbitrary data types while retaining each feature’s characteristic.

No items found.

Where is the AI in HealthTech?

If you suspect that there is an AI bubble in HealthTech – you are 100% right. So where really is the AI in HealthTech?

No items found.

Are deep learning models exponentially more efficient than conventional models in learning complex patterns from DNA sequencing data?

A pilot study utilizing 4174 samples from The Cancer Genome Atlas (#TCGA) has published results of a 77.6% accuracy in predicting cancer types using the raw tumor sequences that integrate all somatic mutations and germline variants.

No items found.

Copy-number signatures - a new family member among cancer mutational signatures

Chromosomal instability (CIN) is a term referring to abnormal cytogenetic behavior such as gains, losses and rearrangements of chromosomes. CIN often leads to serious consequences for a cell and is a hallmark of cancer.

No items found.

Prediction of drug response with mutational signatures. Correlated mutational signatures and the drug phenotyping

There is strong evidence that alterations in the cancer genome can significantly affect the sensitivity and probability of response to treatment.

No items found.

What do we know about somatic noncoding mutation patterns in cancer?

Over the last couple of years, scientists were able to identify many somatic driver mutations in protein-coding regions of the genome. This part of DNA comprises only 2% of the human genome. What about the remaining 98%?

No items found.

$100 Human Genome – is that finally possible?

More than twenty years after having the first sequenced human genome, the price of such service had fallen from billions of dollars to just $1000. But that’s not enough!

No items found.